Microsoft word - temp.doc

Ekaterina Gibiansky
Pharmacometric Publications
1994 - 2002
B.R. Yacyshyn, W.Y. Chey, J. Goff, B. Salzberg, R. Baerg, A.L. Buchman,J. Tami, R. Yu, E.
Gibiansky, W.R. Shanahan. Double-blind, placebo-controlled trial of the remission inducing
and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302) in
active, steroid-dependent Crohn’s disease. Gut 51:30-36 (2002)
C. Garnett, B. Birmingham, E. Gibiansky, S. Rubin, P. Plourde. Population Pharmacokinetics of
Tamoxifen In Pediatric females With McCune-Albright Syndrome (MAS). Pharm. Res. (2002) J.S. Barrett, E. Gibiansky, R.D. Hull, A. Planes, H. Pentikis, J.W. Hainer, T.A. Hua, M.
Gastonguay. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther. 2001 Oct;39(10):431-46. L. Gibiansky, E. Gibiansky, R.Z. Yu, and R.S. Geary, Population Pharmacokinetics of ISIS 2302,
E. Gibiansky, L. Gibiansky, S. Bramer. Comparison of nonmem, bootstrap, jackknife and profiling
parameter estimates and confidence intervals for the aripiprazole population PK model. Pharm. Res. (2001) L. Gibiansky, E. Gibiansky. Parameter estimates and confidence intervals for population PK
E. Gibiansky, T. Ludden, S. Mallikaarjun, A. Corey, X. Chen, D. Salazar, S. Bramer. Population
analysis of efficacy and safety of aripiprazole. Pharm. Res. (2001) L. Gibiansky, E. Gibiansky, R.Z. Yu, and R.S. Geary. ISIS 2302: validation of the population PK
model and PK/PD analysis. Pharm. Res. (2001) X. Chen, E. Gibiansky, S. Mallikaarjun, D.E. Salazar, T. Ludden, S.L. Bramer. Population
Pharmacokinetic Analysis Of Aripiprazole. Pharm. Res. (2001) E. Gibiansky, L. Gibiansky T. Jaworski, and M. Grindel, Population Pharmacokinetics of
Poloxamer 188, Clin Pharm Ther, 67(2), 2000. Gibiansky E, Barrett JS, Pentikis HS. A population pharmacokinetic analysis of anti-xa activity of
tinzaparin from a phase III clinical study. Pharm. Res. 16(11): (1999) Gibiansky E, Mallikaarjun S, Chen X, and Bramer S. Covariate selection via model-free population
pharmacokinetics. Eur. J. Pharm. Sci. 8(2): vii-viii (1999) Nedelman JR, Gibiansky E, Cramer J, Kovarik J, Meligeni J, and Robbins B. Multiple-Dose
pharmacokinetics of a long half-life drug: Contributions of mathematical modeling. Eur. J. Drug. Metab. and Pharmacokin. 22:179-184 (1997) Nedelman J, Cramer JA, Robbins B, Gibiansky E, Chang CT, Gareffa S, Cohen A, and Meligeni
J. The Effect of Food on the Pharmacokinetics of Multiple Dose Terbinafine in Young and Elderly Healthy Subjects. J. Biopharm. and Drug Disp., 18:2, 127-138 (1997) Gibiansky E, Mallikaarjun S, and Bramer S. Nonparametric population pharmacokinetics of
cilostazol. Pharm. Res. 14(11):515 (1997) Nedelman JR, Gibiansky E. The variance of a better AUC Estimator for Sparse, Destructive
Sampling in Toxicokinetics. J.Pharm.Sci. 85(8):884-886 (1996) Pai SM, Nedelman JR, Hajian G, Gibiansky E, and Batra VK. Performance of Bailer’s method for
AUC confidence intervals from sparse non-normally distributed drug concentrations in toxicokinetic studies. Pharm. Res. 13(9):1280-1282 (1996) Nedelman JR, Gibiansky E, Robbins BA, Cramer JA, Riefler JF, Lin T, and Meligeni JA.
Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. J. Clin. Pharmocol. 36:451-461 (1996) Gibiansky E. Application of simulation to study design: multiple-dose pharmacokinetics of long
half-life drug. Proceedings of the SCS Multiconference on Simulation in Medical Sciences. 150-153 (1996). Nedelman JR, Karara AH, Chang CT, Gibiansky E, McDonald S, and Robinson WT. Inferring
systemic exposure from a pharmacokinetic screen: model-free and model-based approaches. Stat. In Med. 14:955-968 (1995). Gibiansky E. Multiple minima: phenomena of the data or a drawback of the method? Comparison
of SAS/IML nonlinear optimization routines. Proceedings of 8th NorthEast SAS Users Group Conference. 621-624(1995). Nedelman JR, Gibiansky E, Lau DT. Applying Bailer's method for AUC confidence intervals to
sparse sampling. Pharm. Res. 12:124-128 (1995). Nedelman JR, Gibiansky E, Tse FL, and Babiuk C. Assessing drug exposure in rodent toxicity
studies without satellite animals. J. Pharmacokin. Biopharm. 21:323-334 (1994). E. Gibiansky. Best initial values for nonlinear estimation: stripping algorithm implemented as
SAS/IML routine. Proceedings of the Northeast SAS Users Group Meeting. 559-563 (1994).


Pii: s8756-3282(01)00613-5

A Theoretical Analysis of the Contributions of Remodeling Space, Mineralization, and Bone Balance to Changes in Bone Mineral Density During Alendronate Treatment 1 Rehabilitation Research and Development Center, VA Palo Alto Health Care System, Palo Alto, CA, USA 2 Biomechanical Engineering Division, Mechanical Engineering Department, and 3 School of Medicine, Stanford University, Stanford,

Microsoft word - tgk9_translation.doc

Fixed Income Research Company snapshot: TGK-9 ranks third among Russian peers in terms of instal ed heating capacity and sixth in Issue info terms of instal ed electricity-generating capacity. The company’s revenue structure is balanced between heating revenue (51%), electricity revenue (45%) and other revenue (4%). TGK-9’s generating facilities are located in the Urals and th

© 2008-2018 Medical News